$TYME on NASDAQ
September 07, 2022
TYME Technologies, Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote “FOR” Proposed Merger of Syros and Tyme
May 25, 2022
TYME Technologies, Inc. Reports Fourth Fiscal Quarter and Full Year 2022 Financial and Operating Results
March 29, 2022
TYME Technologies, Inc. Announces Exploration of Strategic Options
March 25, 2022
TYME Technologies, Inc. Announces Changes to its Board of Directors
March 09, 2022
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022
February 11, 2022
TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating Results
January 27, 2022
TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ET
January 26, 2022
TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer
January 03, 2022
TYME Technologies, Inc. to Present at H.C. Wainwright Bioconnect Virtual Conference
December 14, 2021
TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections
December 09, 2021
TYME Technologies, Inc. Announces Oral SM-88 Poster Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
November 08, 2021
TYME Technologies, Inc. Provides Business Update and Announces Second Fiscal Quarter 2022 Financial and Operating Results
November 02, 2021
TYME Technologies, Inc. to Present at Jefferies London Healthcare Conference
October 27, 2021
TYME Technologies, Inc. to Host Conference Call and Webcast on Monday, November 8th at 8:30 AM ET
September 27, 2021
TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor
September 02, 2021
TYME Technologies, Inc. to Present at Upcoming Virtual Healthcare Industry Conferences
August 10, 2021
TYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating Results
August 02, 2021
TYME Technologies, Inc. to Host Conference Call and Webcast on Tuesday, August 10th at 8:30 AM ET
July 26, 2021
Tyme Granted U.S. Patent Claims Covering Use of Tyrosine-Based Drug Delivery Method to Treat Cancer
June 10, 2021
Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Reports Fiscal Year 2021 Financial Results
May 26, 2021
TYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10th at 5:00 PM ET
May 13, 2021
TYME Appoints Frank L. Porfido as Chief Financial Officer
May 10, 2021
TYME Announces Abstract Selected for Publication at the 2021 American Society of Clinical Oncology Annual Meeting
April 01, 2021
TYME Announces Appointment of Dr. Jan M Van Tornout as Acting Chief Medical Officer
February 08, 2021
TYME Announces Closing of $100 Million Registered Direct Offering of Common Stock
February 04, 2021
TYME Provides Business Update and Announces Third Quarter Fiscal 2021 Financial and Operating Results
February 04, 2021
TYME Announces $100 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
February 03, 2021
TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections
December 09, 2020
TYME Announces SM-88 Abstract Selected for Presentation at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium
November 30, 2020
TYME Builds Leadership Team with Announcement of New CEO
November 12, 2020
TYME Provides Business Update and Announces Second Quarter Fiscal 2021 Financial and Operating Results
October 13, 2020
Tyme Technologies to Present at Jefferies Virtual Global Healthcare Conference on November 17-19, 2020
September 15, 2020
TYME’s Phase II Prostate Cancer Study Evaluating SM-88 in Patients with Non-Metastatic Recurrent Prostate Cancer Published in the Journal, Investigational New Drugs
September 14, 2020
Tyme Technologies to Present at BioNJ’s 10th Annual BioPartnering Conference on October 6, 2020
September 09, 2020
Tyme Technologies to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020
September 02, 2020
Tyme Technologies to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020
August 26, 2020
TYME’s Oncology Research Reveals Potential New Oral Therapy TYME-19 in the Fight Against COVID-19
August 21, 2020
Tyme Technologies to Present at the 2020 CHINABIO® Partnering Forum
August 19, 2020
TYME Announces Appointment of John Rothman, Ph.D. to Executive Vice President, Product Development
August 03, 2020
TYME Announces Orphan Drug Designation for SM-88 as Potential Treatment for Patients with Pancreatic Cancer
July 21, 2020
Tyme Technologies to Present at Canaccord 40th Annual Growth Conference on August 13, 2020
July 13, 2020
TYME Provides Business Update and Announces Preliminary First Quarter Fiscal 2021 Financial and Operating Results
July 10, 2020
Tyme Technologies Announces Virtual 2020 Annual Meeting of Stockholders
June 23, 2020
TYME-18 Demonstrates Anti-Cancer Effect in New Preclinical Data Presented at AACR 2020
June 22, 2020
TYME Presents New Preclinical Data Supporting SM-88 Mechanism of Action at AACR 2020
May 28, 2020
TYME Announces Abstracts Selected for Publication at the 2020 American Society of Clinical Oncology Annual Meeting
May 27, 2020
Tyme Technologies to Present at BIO Digital from June 8-12, 2020
May 20, 2020
TYME Announces Fourth Quarter and Fiscal Year 2020 Financial and Operating Results
May 19, 2020
Tyme Technologies to Present at Jefferies Virtual Healthcare Conference on June 3, 2020
May 18, 2020
Health Economic Research Study Presented at ISPOR, and Published in the Journal Value in Health, Demonstrates Reduction in Total Cost of Care with Increased Use of New Medicines for Treatment of Patients with Pancreatic Cancer
- No Recent Filings Found.
